Nuwellis, Inc. · NASDAQ:NUWE
Nuwellis — Investor Presentation (April 2025)
25 slides from Nuwellis's investor presentation, Apr 3, 2025
Slide 1: Making Aquadex the Standard of Care for Fluid Management
Investor Presentation April 2025 Making Aquadex the Standard of Care for Fluid Management
Slide 2: Safe Harbor Statement
Aquadex SmartFlow® is a registered trademarks of Nuwellis, Inc. Aquadex ® is a trademark of Nuwellis, Inc. Safe Harbor Statement Financial and Statistical DataThis presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and othe
Slide 3: Our Mission
3 Our Mission Nuwellis is dedicated to transforming the lives of patients suffering from Fluid Overload through science, collaboration, and innovation.
Slide 4: Nuwellis is at a Strategic Inflection Point
Nuwellis is at a Strategic Inflection Point 1: Pinney, S et. al., J AM Coll Cardiol HF, 2025, ISSN 2213-1779 https://doi.org/10.1016/j.jchf.2024.11.018 Critical Care + Pediatrics Expanding Outpatient Care Bridging Specialties in Care Delivery Now ~80% of our business, reflecting strong demand. Prior
Slide 5: Significant Growth in Critical Care and Pediatrics Drives Strategic Focus
Significant Growth in Critical Care and Pediatrics Drives Strategic Focus 2: Internal Sales Data As critical care and pediatrics now constitute ~80% of our sales, Nuwellis is realigning its resources towards the Critical Care and Pediatrics customer categories to capitalize on their growth.
Slide 6: Hospitals can now obtain up to $1,639 per day for Aquadex in outpatient care
Hospitals can now obtain up to $1,639 per day for Aquadex in outpatient care, improving accessibility and financial viability. 4x Higher Reimbursement APC 5241 APC 5242 Introducing New Outpatient Reimbursement Rate for Aquadex With the reassignment of CPT 0692T, daily reimbursement rates have signif
Slide 7: Financial Incentive for Hospitals to Use Aquadex in Outpatient Setting
Financial Incentive for Hospitals to Use Aquadex in Outpatient Setting Our outpatient customer category boasts a strong pipeline, indicating significant, near-term revenue opportunities. 3: From Premier Applied Sciences database Increased Reimbursement With reimbursements now up to $1,639, outpatien
Slide 8: The Updated Reimbursement Opportunity is a Win-Win Across the Healthcare Ecosystem
The Updated Reimbursement Opportunity is a Win-Win Across the Entire Healthcare Ecosystem PATIENTS Gives easier access to improved, preventative care, enhancing overall quality of life. PAYOR Promotes cost efficiency, reducing expenses across the healthcare system. NUWELLIS Drives business growth an
Slide 9: Expanding Opportunities Across Critical Customer Categories
Expanding Opportunities Across Critical Customer Categories 4: See Appendix Heart Failure $1B Market4 Critical Care $900M Market4 Pediatrics $130M Market4 $2.53B+ TAM Outpatient Treatment $773M Market4 Leveraging growth in critical care, pediatrics, and outpatient settings to maximize market reach a
Slide 10: We Are Progressing Toward Key Milestones In The REVERSE-HF Trial
We Are Progressing Toward Key Milestones In The REVERSE-HF Trial 2022 2023 2024 2025 2026 2027 First Patient 100th Patient February 150th Patient Q3 Enrollment Completion Q1 Study Completion Insights from the REVERSE-HF Trial will support outpatient and critical care strategies by validating the eff
Slide 11: Our Strategic Growth Plan Emphasizes Four Key Efforts
Our Strategic Growth Plan Emphasizes Four Key Efforts 1 2 3 4 We’ve structured our sales and marketing team to ensure seamless execution
Slide 12: Strategic Focus on Critical Care for 2025
Strategic Focus on Critical Care for 2025 Strategically optimizing the patient journey with targeted fluid management solutions that enhance outcomes at every stage. Pre-Op Optimization Post-Op Recovery Alternative to Conventional Methods Optimizes pre-surgery fluid levels, reducing intraoperative r
Slide 13: Critical and widespread incidence of acute kidney injury among cardiac surgery patients
There is a critical and widespread incidence of acute kidney injury among cardiac surgery patients As many as 80% of cardiac surgery patients may have stage 1 or greater CSA-AKI according to the strict, consensus-based guidelines published by the Kidney Disease Improving Global Outcomes (KDIGO) grou
Slide 14: Our Solution Aquadex
Our Solution Aquadex®A clinically superior solution for Fluid Overload7 The only device of its kind in the market 7: Pinney, S et. al., J AM Coll Cardiol HF, 2025, ISSN 2213-1779 https://doi.org/10.1016/j.jchf.2024.11.018
Slide 15: How the Aquadex system works
Filtered blood returns to the patient via the infusion line 5 Blood is taken from the patient via the withdrawal line using proprietary catheter technology 1 The blood is pushed through the filter by the blood pump (0-40 ml per minute) 2 The ultrafiltration pump withdraws fluid across the filter mem
Slide 16: Vivian Our pediatric solution
Vivian™Our pediatric solution
Slide 17: Our Growth and Success in Pediatrics Drive Development of a Dedicated Device
Received 510(k) and launched commercially in Q1 2020. Our Growth and Success in Pediatrics Drive the Development of a Dedicated Device for High-Risk Conditions 8: Table Source: Menon S, et al. CJSN, 2019; 14: 1432-40. Aquadex is currently cleared for use in pediatric patients weighing 20 kg or more
Slide 18: Reappraisal of AVOID-HF Published in JACC: HF in 2025
Reappraisal of AVOID-HF Published in JACC: HF in 2025 Demonstrated Aquadex Significantly Reduces Heart Failure Hospitalizations9 Reassessed clinical benefit of ultrafiltration versus intravenous diuretics in 224 hospitalized heart failure patients. 9: Pinney, S et. al., J AM Coll Cardiol HF, 2025, I
Slide 19: Growth Strategy Will Lead To Meaningful Revenue Expansion And Improved Cash Flow
We Are Confident That Our Growth Strategy Will Lead To Meaningful Revenue Expansion And Improved Cash Flow Cash $5.1 million as of December 31, 2024 NO Debt Operating Expense 26% reduction vs. 2023
Slide 20: Capitalization Overview
Capitalization Overview As of March 31, 2025 Common Equivalents Common Stock 4,373,968 Preferred Stock 69,039 Warrants (weighted avg. exercise price: $5.49) 5,325,058 Options (weighted avg. exercise price: $524.67) 3,385 Fully Diluted 9,771,450
Slide 21: Nuwellis Leadership Team
Nuwellis Leadership Team John Erb Interim Chief Executive Officer John Jefferies, M.D. Chief Medical Officer Megan Cotts Vice President of Clinical Research and Reimbursement Rob Scott Chief Financial Officer Laurent Duhoux Vice President of International Business Development Over 200 years of combi
Slide 22: Investment Highlights
Investment Highlights Strategic Realignment Financial Growth Clinical Advancement Focus on high-growth categories Expanded impact through strategic shifts to outpatient services Consistent upward trajectory in peds and critical care sectors. Leveraging improved reimbursement models Pediatric dedicat
Slide 23: Thank You
Thank You wr nuwellis
Slide 24: Appendix
Appendix 2 ws Nuwellis
Slide 25: Market size sources
Market size sources Heart Failure – Inpatient ($1B+) Incidence of HF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/ Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 Insufficient diuretic response: https://www.ahajournals.org/doi/10.1161/CIRCHEAR